UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 4)

AC IMMUNE SA (Name of Issuer)

Common shares, nominal value CHF 0.02 per share (Title of Class of Securities)

H00263105 (CUSIP Number)
December 31, 2022 (Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
□ Rule 13d-1(c)
⊠ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP NO. H00263105				13 G	Page 2 of 15 Pages		
1.	Name of Repo	Name of Reporting Persons					
	dievini Hopp	BioTech ho	olding GmbH & Co. K	G			
2.			ox if a Member of a Gro				
		¬ (1)					
		(1)					
3.	SEC USE ONI	ΔY					
4.	Citizenship or	Place of Or	ganization				
	Germany						
	•	5.	Sole Voting Power				
			0 common shares				
	ımber of Shares	6.	Shared Voting Power				
	neficially wned by		16,316,742 common	shares (2)			
	Each	7.					
	Reporting						
	With:	0	0 common shares				
		8.	Shared Dispositive P	ower			
			16,316,742 common	shares (2)			
9.	Aggregate Am	ount Benef	icially Owned by Each	Reporting Person			
	16,316,742 common shares ⁽²⁾						
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □						
11.	Percent of Class Represented by Amount in Row (9)						
	19.5% ⁽³⁾						
12.	Type of Report	ing Person	(See Instructions)				
	00						

- This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- Represents shares held of record by dievini.
- (3) This percentage is calculated based on 83,590,948 shares of the Issuer's common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on October 28, 2022.

CUSIP NO. H00263105				13 G	Page 3 of 15 Pages		
1.	Name of Repo	Name of Reporting Persons					
	DH-Capital G	mbH & C	o. KG				
2.			ox if a Member of a Gro	oup (See Instructions)			
		¬ (1)					
		(1)					
3.	SEC USE ONI	ΔY					
4.	Citizenship or	Place of O	ganization				
	Germany						
	J	5.	Sole Voting Power				
			0 common shares				
	ımber of	6.	Shared Voting Power	<u> </u>			
	Shares neficially	0.	Shared voting rower				
	wned by		16,316,742 common	shares (2)			
	Each	7.	7. Sole Dispositive Power				
]	Reporting Person		0 common shares				
	With:	8.	Shared Dispositive P	ower			
			16 246 542	. (2)			
		D (16,316,742 common				
9.	Aggregate Am	ount Benef	icially Owned by Each	Kehotting Ketson			
	16,316,742 common shares ⁽²⁾						
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) \Box						
11	Descript of Class Descripted by Assessment in Description						
11.	Percent of Class Represented by Amount in Row (9)						
	19.5% ⁽³⁾						
12.	Type of Report	ing Person	(See Instructions)				
	00						

- This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- Represents shares held of record by dievini.
- (3) This percentage is calculated based on 83,590,948 shares of the Issuer's common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on October 28, 2022.

COSIP N	O. H00263105		Page 4 of 15 Pages				
1.	Name of Repor	Name of Reporting Persons					
	OH Beteiligun	gen GmbI	H & Co. KG				
2.			ox if a Member of a Group (See Instructions)				
		(1)					
3.	SEC USE ONI	Υ					
4.	Citizenship or	Place of Or					
	C						
	Germany	5.	Colo Veting Dover				
		5.	Sole Voting Power				
NT			0 common shares				
	ımber of Shares	6.	Shared Voting Power				
Ber	neficially		16.216.742				
	wned by Each		16,316,742 common shares ⁽²⁾				
	Each 7. Reporting		Sole Dispositive Power				
	Person		0 common shares				
	With:	8.	Shared Dispositive Power				
			16,316,742 common shares ⁽²⁾				
9.	Aggregate Am	ount Benef	icially Owned by Each Reporting Person				
	16,316,742 common shares ⁽²⁾						
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □						
11.	Percent of Class Represented by Amount in Row (9)						
	19.5% ⁽³⁾						
⁽²⁾ 12.	Type of Report	ing Person	(See Instructions)				
	00						
	•						

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents shares held of record by dievini.
- (3) This percentage is calculated based on 83,590,948 shares of the Issuer's common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on October 28, 2022.

CUSIP NO. H00263105				13 G	Page 5 of 15 Pages		
				•			
1.	Name of Repo	Name of Reporting Persons					
	Dietmar Hopp)					
2.	Check the App	ropriate Bo	ox if a Member of a Gro	up (See Instructions)			
	() E ()	¬ (1)					
		(1)					
3.	SEC USE ONI	_Y					
4.	Citizenship or	Place of O	ganization				
	Germany						
		5.	Sole Voting Power				
			0 common shares				
	ımber of Shares	6.	Shared Voting Power	•			
Be	neficially		16,316,742 common	charge (2)			
0	wned by Each	7.	Sole Dispositive Power				
	eporting	, ·	_	vci			
	Person With:		0 common shares				
	**1411.	8.	Shared Dispositive P	ower			
			16,316,742 common	shares (2)			
9.	Aggregate Am	ount Benef	icially Owned by Each	Reporting Person			
	16,316,742 common shares ⁽²⁾						
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □						
11.	Percent of Class Represented by Amount in Row (9)						
	19.5% ⁽³⁾						
12.	Type of Report	ing Person	(See Instructions)				
	IN						

- This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- Represents shares held of record by dievini.
- (3) This percentage is calculated based on 83,590,948 shares of the Issuer's common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on October 28, 2022.

CUSIP NO. H00263105				13 G	Page 6 of 15 Pages		
1.	Name of Repo	Name of Reporting Persons					
	Oliver Hopp						
2.	Check the App	ropriate Bo	ox if a Member of a Gro	up (See Instructions)			
	() = ()	¬ (1)					
		(1)					
3.	SEC USE ONI	_Y					
4.	Citizenship or	Place of O	ganization				
	Germany						
		5.	Sole Voting Power				
			0 common shares				
	ımber of Shares	6.	Shared Voting Power	•			
Be	neficially		16 216 742	.1(2)			
O	wned by Each	7.	16,316,742 common shares ⁽²⁾ Sole Dispositive Power				
	eporting	/.	Sole Dispositive Pow	vei			
	Person With:		0 common shares				
	vviui;	8.	Shared Dispositive P	ower			
			16,316,742 common	shares (2)			
9.	Aggregate Am	ount Benef	icially Owned by Each	Reporting Person			
	16,316,742 coi	nmon share	_{es} (2)				
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □						
11.	Percent of Class Represented by Amount in Row (9)						
	19.5 ⁽³⁾						
12.	Type of Report	ing Person	(See Instructions)				
	IN						

- This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- Represents shares held of record by dievini.
- (3) This percentage is calculated based on 83,590,948 shares of the Issuer's common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on October 28, 2022.

CUSIP NO. H00263105			_	13 G	Page 7 of 15 Pages		
				•			
1.	Name of Repor	Name of Reporting Persons					
	Daniel Hopp						
2.	Check the App	ropriate Bo	ox if a Member of a Gro	up (See Instructions)			
	(a) □ (b)	(1)					
3.	SEC USE ONI						
5.	SEC COL OIL						
4.	Citizenship or l	Place of O	rganization				
	Germany						
	· · · · · · · · · · · · · · · · · · ·	5.	Sole Voting Power				
			0 common shares				
	umber of Shares	6.	Shared Voting Power	•			
Be	neficially			. (2)			
O	wned by Each		16,316,742 common shares ⁽²⁾				
R	eporting	7.	Sole Dispositive Power				
	Person With:		0 common shares				
	WILLI.	8.	Shared Dispositive P	ower			
			16,316,742 common	shares (2)			
9.	Aggregate Amo	ount Benef	ficially Owned by Each				
	16,316,742 common shares ⁽²⁾						
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □						
	Sheen in the 1156 contain in 11611 (5) Encluded Seriam Shares (See Installations)						
11.	Percent of Class Represented by Amount in Row (9)						
	19.5 ⁽³⁾						
12.		ing Person	(See Instructions)				
	IN						
	<u> </u>						

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents shares held of record by dievini.
- (3) This percentage is calculated based on 83,590,948 shares of the Issuer's common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on October 28, 2022.

CUSIP NO. H00263105				13 G	Page 8 of 15 Pages	
				•		
1.	Name of Repor	rting Perso	ns			
	Prof. Dr. Fried	lrich von 1	Bohlen und Halbach			
2.	Check the App	ropriate Bo	ox if a Member of a Gro	up (See Instructions)		
		— (1)				
	()	□ ⁽¹⁾				
3.	SEC USE ONI	Y				
4.	Citizenship or	Place of O	ganization			
	Germany					
	•	5.	Sole Voting Power			
			0 common shares			
-	ımber of Shares	6.	Shared Voting Power	•		
Bei	neficially		687,128 common sha	(2)		
	wned by Each	7				
	eporting	7.	Sole Dispositive Pow	ver		
	Person With:		0 common shares			
	wim:	8.	Shared Dispositive P	ower		
			687,128 common sha	ares (2)		
9.	Aggregate Am	ount Benef	icially Owned by Each			
	687,128 common shares ⁽²⁾					
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □					
11.	Percent of Class Represented by Amount in Row (9)					
	$0.8\%^{(3)}$					
12.	Type of Report	ing Person	(See Instructions)			
	IN					

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH
 Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr.
 von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH
 Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting
 Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents shares held of record by Bohlini invest GmbH, a company wholly owned and controlled by Dr. von Bohlen.
- (3) This percentage is calculated based on 83,590,948 shares of the Issuer's common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on October 28, 2022.

CUSIP NO. H00263105				13 G	Page 9 of 15 Pages		
				-			
1.	Name of Repo	rting Perso	ns				
	Prof. Dr. Chri	stof Hettic	ch				
2.			ox if a Member of a Gro	oup (See Instructions)			
		-					
		□ ⁽¹⁾					
3.	SEC USE ONI	LY					
4.	Citizenship or	Place of O	rganization				
	Germany						
		5.	Sole Voting Power				
			0 common shares				
	ımber of Shares	6. Shared Voting Power					
	snares neficially						
	wned by		470,779 common shares ⁽²⁾				
R	Each eporting	7.	Sole Dispositive Pow	ver			
]	Person		0 common shares				
	With:	8.	Shared Dispositive P	'ower			
				(2)			
	<u> </u>		470,779 common sha				
9.	Aggregate Am	ount Benei	ficially Owned by Each	Keporting Person			
	470,779 common shares ⁽²⁾						
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) \Box						
11.	Percent of Class Represented by Amount in Row (9)						
	(2)						
	0.6% ⁽³⁾						
12.	Type of Report	ing Person	(See Instructions)				
	IN						

- This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- Represents shares held of record by 4H invest GmbH, a company wholly owned and controlled by Dr. Hettich.
- (3) This percentage is calculated based on 83,590,948 shares of the Issuer's common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on October 28, 2022.

COSII IV	0.1100203103		rage 10 01 13 rages				
1.	Name of Repor	Name of Reporting Persons					
	Dr. Mathias H	othum					
2.	Check the App	ropriate Bo	ox if a Member of a Group (See Instructions)				
	(a) (b)	(1)					
3.	SEC USE ONI	Υ					
4.	Citizenship or	Place of O	ganization				
	Germany						
		5.	Sole Voting Power				
NT.	1 C		0 common shares				
S	ımber of Shares	6.	Shared Voting Power				
	neficially wned by		360,820 common shares ⁽²⁾				
	Each eporting	7.	Sole Dispositive Power				
I	Person		0 common shares				
	With:	8.	Shared Dispositive Power				
			360,820 common shares ⁽²⁾				
9.	Aggregate Am	ount Benef	icially Owned by Each Reporting Person				
	360,820 comm	on shares (2)				
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) \Box						
11.	Percent of Class Represented by Amount in Row (9)						
	0.4 (3)						
12.	Type of Report	ing Person	(See Instructions)				
	IN						

Dago 10 of 15 Dagos

CUSID NO. H0026210E

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents shares held of record by MH-LT-Investments GmbH, a company wholly owned and controlled by Dr. Hothum.
- (3) This percentage is calculated based on 83,590,948 shares of the Issuer's common shares reported to be issued by the Issuer as of September 30, 2022, as reported on the Issuer's Form 6-K filed on October 28, 2022.

This Amendment No. 4 to Schedule 13G (this "Amendment") amends the Schedule 13G filed with the Securities and Exchange Commission on May 5, 2022 by the Reporting Persons (the "Statement") with respect to common shares, nominal value CHF 0.02 per share (the "Shares") of AC Immune SA, a Swiss stock corporation (the "Issuer").

Page 11 of 15 Pages

Name of Issuer: Item 1(a)

AC Immune SA

Address of Issuer's principal executive offices: Item 1(b)

EPFL Innovation Park Building B 1015 Lausanne Switzerland

Items 2(a) Name of Reporting Persons filing:

dievini Hopp BioTech holding GmbH & Co. KG ("dievini") DH-Capital GmbH & Co. KG ("DH-Capital") OH Beteiligungen GmbH & Co. KG ("OH Beteiligungen") Dietmar Hopp Oliver Hopp Daniel Hopp Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen")

Prof. Dr. Christof Hettich ("Dr. Hettich") Dr. Mathias Hothum ("Dr. Hothum")

Item 2(b) Address or principal business office or, if none, residence:

The address of the principal business office of dievini, Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum is c/o dievini Hopp BioTech holding GmbH & Co. KG, Johann-Jakob-Astor Straße 57, 69190 Walldorf, Germany.

The address of the principal business office of DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG is Opelstraße 28, 68789 St. Leon-Rot, Germany.

The address of the principal business office of Oliver Hopp is Johann-Jakob-Astor-Straße 59, 69190 Walldorf, Germany.

The address of the principal business office of Daniel Hopp is Johann-Jakob-Astor-Straße 57, 69190 Walldorf, Germany.

The address of Dr. Hettich is Silcherstraße 6, 68723 Schwetzingen, Germany.

Citizenship or Place of Organization

The address of Dr Hothum is Bürgermeister-Willinger-Straße 3, 69190 Walldorf, Germany.

The address of Dr von Bohlen is Neuenheimer Landstraße 4, 69120 Heidelberg, Germany.

Item 2(c) Citizenship:

Nama

Name	Citizenship or Place of Organization
Dievini	Germany
DH-Capital	Germany
OH Beteiligungen	Germany
Dietmar Hopp	Germany
Oliver Hopp	Germany
Daniel Hopp	Germany
Dr. von Bohlen	Germany
Dr. Hettich	Germany
Dr. Hothum	Germany

CUSIP NO. H00263105	13 G	Page 12 of 15 Pages

Item 2(d) Title of class of securities:

Common shares, nominal value CHF 0.02 per share

Item 2(e) CUSIP No.:

H00263105

Item 3 If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

Not applicable.

Item 4 Ownership

With respect to the beneficial ownership of each Reporting Person, see Items 5 through 11 of the cover pages to this Schedule 13G, which are incorporated herein by reference. These items reflect the beneficial ownership of each Reporting Person as of December 31, 2022.

DH-Capital and OH Beteiligungen are collectively the holders of 100% of the limited partner interest in dievini and therefore, control the voting and dispositive decisions of dievini together and may be deemed to beneficially own the shares held by dievini. Dietmar Hopp, Oliver Hopp and Daniel Hopp are the ultimate controlling persons of dievini, DH-Capital and OH Beteiligungen, and control the voting and investment decisions of the ultimate parent company of dievini and therefore, may be deemed to beneficially own the shares held by dievini by virtue of their status as controlling persons of dievini.

CUSIP N	IO. H00263105 13 G Page 13 of 15 Pages			
Item 5	Ownership of Five Percent or Less of a Class			
	If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: \Box			
Item 6	Ownership of More than Five Percent on Behalf of Another Person			
	Not applicable.			
Item 7	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person			
	Not applicable.			
Item 8	Identification and Classification of Members of the Group			
	Not applicable.			
Item 9	Notice of Dissolution of Group			
	Not applicable.			
Item 10	Certifications			
	Not applicable.			

CUSIP NO. H00263105 13 G Page 14 of 15 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 10, 2023

DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG

By: dievini Verwaltungs GmbH

its General Partner

By: /s/ Dr. Marc Hauser

Name: Dr. Marc Hauser Title: Attorney-in-fact

DH-CAPITAL GMBH & CO. KG

By: DH Verwaltungs GmbH its General Partner

By: /s/ Dr. Marc Hauser

Name: Dr. Marc Hauser Title: Attorney-in-fact

OH BETEILIGUNGEN GMBH & CO. KG

By: OH Verwaltungs GmbH its General Partner

/s/ Dr. Marc Hauser

Name: Dr. Marc Hauser Title: Attorney-in-fact

/s/ Dr. Marc Hauser as attorney-in-fact

DIETMAR HOPP

/s/ Dr. Marc Hauser as attorney-in-fact

OLIVER HOPP

/s/ Dr. Marc Hauser as attorney-in-fact

DANIEL HOPP

/s/ Dr. Marc Hauser as attorney-in-fact

FRIEDRICH VON BOHLEN UND HALBACH

/s/ Dr. Marc Hauser as attorney-in-fact

CHRISTOF HETTICH

/s/ Dr. Marc Hauser as attorney-in-fact

MATHIAS HOTHUM

CUSIP NO. H00263105		13 G	Page 15 of 15 Pages		
Exhibit(s):					
1 – Power of Attorney	- Power of Attorney Incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons on February 14, 2017 with respect to the common shares of the Issuer.				
2 - Joint Filing Statement	<u>Incorporated by reference to Exhibit 99.2 to the Schedule 13G filed by the Reporting Persons on February 14, 2017 with respect to the common shares of the Issuer.</u>				